New B7 Family Checkpoints in Human Cancers

Ni, Ling; Dong, Chen

doi:10.1158/1535-7163.mct-16-0761

Cited by 204 publications

(215 citation statements)

References 102 publications

(141 reference statements)

Supporting

Mentioning

210

Contrasting

Order By: Relevance

“…34,35 The B7 family, interferon and STAT1 were found to be positively correlated with the risk score, while HCK, IgG, LCK, MHC-I and MHC-II were negatively correlated with the risk score ( Figure 3A). 34,35 The B7 family, interferon and STAT1 were found to be positively correlated with the risk score, while HCK, IgG, LCK, MHC-I and MHC-II were negatively correlated with the risk score ( Figure 3A).…”

Section: Tumour Immune Landscape and Genomic Associationmentioning

confidence: 99%

Systematic construction and validation of an immune prognostic model for lung adenocarcinoma

Luo

Lei

Zhang

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD), the most common non-small-cell lung cancer, is characterized by a dense lymphocytic infiltrate, which indicates that the immune system plays an active role in the development and growth of this cancer. However, no investigations to date have proposed robust models for predicting survival outcome for patients with LUAD in terms of tumour immunology. A total of 761 LUAD patients were included in this study, in which the database of The Cancer Genome Atlas (TCGA) was utilized for discovery, and the Gene Expression Omnibus (GEO) database was utilized for validation. Bioinformatics analysis and R language tools were utilized to construct an immune prognostic model and annotate biological functions.Lung adenocarcinoma showed a weakened immune phenotype compared with adjacent normal tissues. Immune-related gene sets were profiled, an immune prognostic model based on 2 immune genes (ANLN and F2) was developed with the TCGA database to distinguish cases as having a low or high risk of unfavourable prognosis, and the model was verified with the GEO database. The model was prognostically significant in stratified cohorts, including stage I-II, stage III-IV and epidermal growth factor receptor (EGFR) mutant subsets, and was considered to be an independent prognostic factor for LUAD. Furthermore, the low-and high-risk groups showed marked differences in tumour-infiltrating leucocytes, tumour mutation burden, aneuploidy and PD-L1 expression. In conclusion, an immune prognostic model was proposed for LUAD that is capable of independently identifying patients at high risk for poor survival, suggesting a relationship between local immune status and prognosis. K E Y W O R D Sbiomarkers, immune prognostic model, immunology, lung adenocarcinoma, overall survival

show abstract

Section: Tumour Immune Landscape and Genomic Associationmentioning

confidence: 99%

Systematic construction and validation of an immune prognostic model for lung adenocarcinoma

Luo

Lei

Zhang

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…5 PD-L1/PD-1 has become a hot area of research in recently years. Ten members are included in the B7/CD28 family, including B7-1/CD28, B7-2/cytotoxic T lymphocyte antigen 4 (CTLA-4), ICOS-L/ICOS and programmed cell death 1 (PD-1)/PD-1 ligand (PD-L1).…”

Section: Introductionmentioning

confidence: 99%

“…Ten members are included in the B7/CD28 family, including B7-1/CD28, B7-2/cytotoxic T lymphocyte antigen 4 (CTLA-4), ICOS-L/ICOS and programmed cell death 1 (PD-1)/PD-1 ligand (PD-L1). 5 PD-L1/PD-1 has become a hot area of research in recently years. 6,7 The B7/CD28 family regulates the proliferation and function of T cells as antigen-presenting cells (APCs).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Overexpression of B7H5/CD28H is associated with worse survival in human gastric cancer

Chen

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Gastric cancer (GC) is a common malignancy with low 5-year overall survival (OS).Recently, immune therapy has been used to treat cancer. B7H5 and CD28H are novel immune checkpoint molecules. However, the prognostic value of B7H5/CD28H expression in patients with GC remains unclear. In this study, seventy-one patients diagnosed with GC were included in this study. Patients' GC tissues and matched adjacent tissue constructed a tissue microarray. The expression levels of B7H5 and CD28H were examined using immunohistochemistry. Correlations between the expression of B7H5 and CD28H and the clinical data were evaluated. We found that the expression of B7H5 and CD28H (both P = .001) were higher in GC tumour tissues than in adjacent noncancerous tissues. B7H5/CD28H expression acted as an independent predictive factor in the OS of patients with GC. High expression of B7H5 and CD28H predicted poor outcome.Patients in the B7H5+CD28H+ group had a lower 5-year OS compared with patients in the B7H5−CD28− group (4.5% vs 55.6%, P = .001). A significant difference was found in the 5-year OS between patients in the B7H5+CD28H− and B7H5+CD28H+ groups (33.5% vs 4.5%, P = .006). However, there was no correlation between B7H5 and CD28H expression (P = .844). Therefore, B7H5 and CD28H expression are up-regulated in GC and are independent prognostic factors for overall survival in patients with GC. Although there was no correlation between B7H5 and CD28H expression, high expression of B7H5 and CD28H predicts poor prognosis, especially when both are highly expressed. K E Y W O R D SB7 family checkpoints, B7H5, CD28H, gastric cancer, immunotherapy

show abstract

“…(4,19) The newly discovered member of the B7 family B7-H6 interacts with its receptor on NK cells, namely, NKp30, and plays an important role in NK cell-mediated immune responses. (12) Abnormal B7-H6 expression is found in many human cancer types, suggesting that B7-H6 has important clinical significance.…”

Section: Discussionmentioning

confidence: 99%